

NANOVIRICIDES, INC.  
Form 8-K  
June 02, 2014

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) **May 29, 2014**

**NANOVIRICIDES, INC.**  
(Exact Name of Registrant as Specified in Its Charter)

**Nevada** **000-1379006** **76-0674577**  
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

**135 Wood Street, Suite 205**

**West Haven, Connecticut**  
(Address of Principal Executive Offices)

**06516**  
(Zip Code)

**(203) 937-6137**

(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: NANOVIRICIDES, INC. - Form 8-K

- “ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- “ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- “ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- “ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On May 29, 2014, the Registrant's Chief Executive Officer gave a presentation at the Marcum LLP MicroCap Conference. A copy of the presentation is attached and furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference

**SIGNATURES**

**PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED.**

**NANOVIKIDES, INC.**

Date: June 2, 2014 By: */s/ Eugene Seymour, MD*  
Name: Eugene Seymour

Title: Chief Executive Officer

INDEX TO EXHIBITS

**Item 9.01. Financial Statements and Exhibits.**

Exhibit 99.1 Presentation materials.